

****New release June 2011****

MarketVIEW: Group A Streptococcus vaccines (CAT: VAMV027)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	MarketVIEW: Group A Streptococcus vaccines – Global market forecast
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	<i>Novel childhood/endemic vaccines</i>
Product (if applicable)	:	CAT No: VAMV027, published June 2011

Background

Group A Streptococcus (GAS) or *Streptococcus pyogenes* is a Gram-positive organism commonly found in the throat and skin. Although colonization with GAS is mostly harmless, the bacteria can cause a wide spectrum of diseases and inflammatory sequelae. GAS infections range from mild superficial infections such as pharyngitis “strep throat” to severe invasive life-threatening diseases (iGAS) such as necrotizing fasciitis (NF) or “flesh eating disease”. GAS is also responsible for rheumatic heart disease (RHD) which is estimated to kill thousands of people each year, mostly in developing regions.

A vaccine to prevent infections by GAS is highly desirable. However, its development has been hindered by historical safety concerns and uncertain commercial viability in light of other priority diseases such as malaria, TB and HIV/AIDS. Despite GSK/ID Biomedical’s Streptavax being put on hold at Phase II clinical testing, major vaccine players still have an active interest in GAS vaccine development.

This **MarketVIEW** product is a comprehensive opportunity assessment investigating the commercial potential of GAS vaccine indications for the Western developing world as well as ROW/emerging markets. The product consists of an executive presentation detailing all relevant topics pertain to GAS vaccine commercialization including ideal target product profile, clinical development issues and competitive environment. Also included is a detailed MS Excel value/volume demand forecast to 2030 for all relevant indications/regions. This product is a ideal tool to aid early stage decision making in GAS vaccine development.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Group A Streptococcus disease epidemiology/ dynamics, current treatments and novel immunotherapeutics (pipeline). Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of bacterial vaccines has also been utilised. *****See Bibliography for exact sources.**

PRODUCT CONTENTS:

Published June 2011 (CAT No: VAMV027)

****This product is composed of a forecast model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

- Contents
- Contents
- Authors Note
- Executive summary
- GAS vaccine: commercial model – key outputs
- GAS vaccine: possible indications and regional markets
- GAS vaccine: commercial summary (Western world)
- GAS vaccine: commercial summary (ROW/emerging markets)
- GAS vaccine: pharyngitis indication (West) (\$ 000s) to 2030
- GAS vaccine: iGAS indication 1 (West) (\$ 000s) to 2030
- GAS vaccine: iGAS indication 2 (West) (\$ 000s) to 2030
- GAS vaccine: ARF/RHD indication (ROW) (\$ 000s) to 2030
- Group A Streptococcus: brief background and disease indications
- The pathogen
- GAS: classification of diseases
- GAS disease epidemiology: key parameters
- GAS – global pathogen perspective
- Invasive GAS (iGAS) syndromes: morbidity/mortality
- Notes on Streptococcal pharyngitis
- Acute rheumatic fever (ARF): clinical features
- Rheumatic heart disease (RHD): clinical features
- ARF/RHD – disease continuum
- Untreated recurrent ARF causes severe RHD and death
- GAS: designing the ideal vaccine
- Proteins involved in GAS pathogenesis
- Challenges to developing GAS vaccines
- GAS vaccines: historical safety concerns
- GAS vaccine opportunity: ideal product profile
- GAS vaccines: notes on clinical development strategy
- Possible pathways for a global GAS vaccine
- GAS vaccine: possible deployment strategies
- GAS vaccine summary: Western developed markets
- GAS vaccine: potential benefit in Western developed markets
- GAS vaccine: physician perspectives on critical attributes
- Risk groups for iGAS indication

CONTINUED.....

GAS vaccine summary: developing markets
GAS vaccine summary: potentia benefit in developing markets
GAS vaccine: estimating commercial potential
GAS vaccine: modelling strategy – Western indications
Prevention of GAS pharyngitis (West) – assumptions per country
Prevention iGAS (West) – assumptions per country
GAS vaccine: modelling strategy – Emerging/ROW indications
Emerging/ROW regions: included in model
Notes on target populations: ARF/RHD
Predicted order of vaccine rollout: Emerging/RHD
ARF/RHD primary prevention: detailed assumptions per country
Pricing case studies for a GAS vaccine (ROW/emerging)
Funding GAS vaccines: issues
Key future challenges with ARF/RHD vaccine indication
Limitations of model
GAS vaccines: competitive situation/case studies
Notable GAS vaccine approaches to date
Major competitor summary
Appendix I – Further epidemiology
Invasive GAS epidemiology - global overview
Invasive GAS epidemiology – focus on US
Invasive GAS epidemiology – focus on EU
Bibliography
Disclaimer
About **VacZine Analytics**

PAGES: ~80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
CHARTS (Western)
CHARTS (ROW, emerging)
Western indication summaries ==>>
Pharyngitis (3-6 yrs) summary
iGAS (20-65 yrs risk) summary
iGAS (>65 yrs) LTC summary
ROW indication summaries ==>
ARF & RHD (4 – 6 yrs) summary
Pharyngitis (West) ==>
USA
Canada
UK
France
Germany
Italy
Spain
Australia
Other EU
iGAS (West) ==>
>65 yrs (LTC)
USA
Canada
UK



CONTINUED.....

France
Germany
Italy
Spain
Australia
Other EU
20 – 65 yrs (at risk)
USA
Canada
UK
France
Germany
Italy
Spain
Australia
Other EU
ARF & RHD (Emerging/ROW) =>
Brazil
Russia
India
China
Mexico
SubAFR
SouCentASI
Asia Other
LATAM
MENA
PACIFICind
EasternEur
Source material
Region definition and forecast
International Birth Cohort
Population database
Back page

WORKSHEETS: ~60



PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$8995.00/ GBP £5450.00 (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. US Centers for Disease Control and Prevention. Group A Streptococcal Disease. Available at: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/Groupastreptococcal_g.htm. Accessed August 2010
2. Martin JM., et al. Group A *Streptococcus*. 2006. *Semin Pediatr Infect Dis* 17: 140-148
3. The World Health Organisation (WHO). A Review of the technical Basis for the Control of the Conditions Associated with Group A Streptococcal Infections. Available at: http://whqlibdoc.who.int/hq/2005/WHO_FCH_CAH_05.08.pdf Accessed August 2010.
4. Carapetis JR et al. The global burden of group A streptococcal diseases. *Lancet Infect Dis* 2005;5:685-94
5. World Health Organization. The global burden of disease: 2004 update. Geneva, World Health Organization, 2008. Available at <http://www.who.int/>. Accessed June 2011
6. Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive Group A Streptococcal disease among household contacts of case-patients is prophylaxis warranted? *JAMA*. 1998;279:1206-1210.
7. Feely EA. Necrotizing Fasciitis. Diagnostic Modalities. Available at: http://intmedweb.wfubmc.edu/grand_rounds/1998/necrotizing_fasciitis.html#Treatment. Accessed July 2008.
8. Loughlin RE., et al. The epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications. *Clin Infect Dis*. 2007; 45:853-62
9. Linder JA, Bates DW, Lee GM, Finkelstein JA. Antibiotic treatment of children with sore throat. *JAMA*. Nov 9 2005;294(18):2315-2322.
10. Pfoh E, Wessels MR, Goldmann D, Lee GM. Burden and economic cost of group A streptococcal pharyngitis. *Pediatrics*. Feb 2008;121(2):229-234
11. Carapetis JR et al. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? *Epidemiol Infect*. 2000 Apr;124(2):239-44.
12. Kotby A. Rheumatic Fever In The New Millennium. *Pediatrics* 2008;121;S95
13. Hanna JN et al. The epidemiology of acute rheumatic fever in Indigenous people in north Queensland. *Aust N Z J Public Health*. 2005 Aug;29(4):313-7.
14. Saxena A et al. Does Echocardiography Aid in the Diagnosis of Rheumatic Fever with Carditis in Children? Experience from a Country with High Prevalence of Rheumatic Heart Disease. 5th World Congress of Pediatric Cardiology and Cardiac Surgery, June 21 to June 26 2009, Cairns, Australia.
15. Steer AC et al. Acute rheumatic fever and rheumatic heart disease in Fiji: prospective surveillance, 2005-2007. *Med J Aust*. 2009 Feb 2;190(3):133-5.
16. Borges F et al. [Clinical and demographic characteristics of 99 episodes of rheumatic fever in Acre, the Brazilian Amazon]. [Article in Portuguese]. *Arq Bras Cardiol*. 2005 Feb;84(2):111-4.
17. Mota C et al. The spectrum of presentation and long term evaluation of valvar lesions in 1066 acute episodes of rheumatic fever in children and adolescents. 5th World Congress of Pediatric Cardiology and Cardiac Surgery, June 21 to June 26 2009, Cairns, Australia
18. Meira ZM et al. Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents. *Heart*. 2005 Aug;91(8):1019-22.
19. Tubridy-Clark M et al. Subclinical carditis in rheumatic fever: a systematic review. *Int J Cardiol*. 2007 Jun 25;119(1):54-8.
20. Rayamajhi A et al. First-episode versus recurrent acute rheumatic fever: is it different? *Pediatr Int*. 2009 Apr;51(2):269-75
21. Sriskandan S., et al. *Streptococcus pyogenes*. Insight into the function of the streptococcal superantigens. *Int J Biochem & Cell Biol* 2007; 39; 12-19
22. Dey N, McMillan DJ, Yarwood PJ, et al. High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. *Clinical Infectious Diseases*. Jan 1 2005;40(1):46-51.
23. Smeesters PR, Vergison A, Campos D, de Aguiar E, Miendje Deyi VY, Van Melderen L. Differences between Belgian and Brazilian group A *Streptococcus* epidemiologic landscape. *PLoS ONE* [Electronic Resource]. 2006;1:e10
24. Massell BF., et al. Rheumatic fever following streptococcal vaccination. Report of three cases. *JAMA* 1969;207(6):1115-9
25. Lancefield RC. The antigenic complex of *Streptococcus hemolyticus* I. Demonstration of type specific substance in extract of *Streptococcus hemolyticus*. *J Exp Med* 1928; 47:91-103
26. Bisno AL, Gerber MA, Gwaltney JM, Jr., Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. *Infectious Diseases Society of America*. *Clin Infect Dis*. Jul 15 2002;35(2):113-125
27. Gerber MA., et al. Physicians opinions about critical attributes of a potential group A streptococcal vaccine. *Vaccine* 28 (2010) 7155-7160
28. Recommended Immunization Schedule for Persons aged 0 through 6 years. United States 2011. Available at: Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. *Vaccine* 2008; 26:914-23

29. Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. *Vaccine* 2008; 26:914-23
30. Tuberculosis Vaccines: The case for Investment. A report prepared by BIO Ventures for Global Health. October 2006.
31. Boston Consulting Group. Market Assessment for Malaria Vaccines. January 2005. Available at: http://www.malariavaccine.org/files/Market-Assessment-18Jan05-LBBOS_000.pdf. Accessed June 2010.
32. The World Health Organisation. Yellow Fever Initiative. Providing an opportunity of a lifetime. Available at: <http://www.who.int/csr/disease/yellowfev/YFibrochure.pdf>. Accessed June 2010
33. PneumoACTION. Pneumo Slide Set. Chapter 4. Preventing Pneumonia & Pneumococcal disease. Available at: <http://www.preventpneumo.org/data-tools/slides.cfm>. Accessed April 2011
34. Unicef. Supplies and Logistics. Vaccine Price Data. Available at: http://www.unicef.org/supply/index_57476.html . Accessed April 2011
35. Discussion papers on Child Health. Group A streptococcal vaccine development: current status and issues of relevance to less developed countries. WHO 2005.
36. GAVI Alliance Strategic Financial Forecast. Available at: http://www.gavialliance.org/resources/20brd_10aFinancial_Forecast.pdf. Accessed July 2010
37. World Health Organization. Group A streptococcal vaccine development: current status and issues of relevance to less developed countries. Published 2005.
38. Kabanova A et al. Evaluation of a Group A Streptococcus synthetic oligosaccharide as a vaccine candidate. *Vaccine* 29 (2011) 104 -111
39. Centers for Disease Control and Prevention. 2003. Active Bacterial Core Surveillance (ABCs) report. Group A Streptococcus, 2006. Available at: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas06.pdf>. Accessed June 2011
40. Lamagni TL et al. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. *Eurosurveillance* 2005; Vol. 10. Issues 7-9

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009